Anobile DP, Salaroglio IC, Tabbo F, La Vecchia S, Akman M, Napoli F, Bungaro M, Benso F, Aldieri E, Bironzo P, Kopecka J, Passiglia F, Righi L, Novello S, Scagliotti GV, Riganti C (2023) Autocrine 17-beta-Estradiol/Estrogen receptor-alpha loop determines the response to immune checkpoint inhibitors in non-small cell lung cancer. Clin Cancer Res 29(19):3958–3973. https://doi.org/10.1158/1078-0432.CCR-22-3949

Article  PubMed  Google Scholar 

Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, Yokoi T, Chiappori A, Lee KH, de Wit M, Cho BC, Bourhaba M, Quantin X, Tokito T, Mekhail T, Planchard D, Kim YC, Karapetis CS, Hiret S (2017) Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. N Engl J Med 377(20):1919–1929. https://doi.org/10.1056/NEJMoa1709937

Article  PubMed  Google Scholar 

Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, Kurata T, Chiappori A, Lee KH, de Wit M, Cho BC, Bourhaba M, Quantin X, Tokito T, Mekhail T, Planchard D, Kim YC, Karapetis CS, Hiret S, Ostoros G, Kubota K, Gray JE, Paz-Ares L, de Castro Carpeño J, Faivre-Finn C, Reck M, Vansteenkiste J, Spigel DR, Wadsworth C, Melillo G, Taboada M, Dennis PA, Özgüroğlu M (2018) Overall survival with Durvalumab after chemoradiotherapy in stage III NSCLC. N Engl J Med 379(24):2342–2350. https://doi.org/10.1056/NEJMoa1809697

Article  PubMed  Google Scholar 

Auperin A, Le Pechoux C, Rolland E, Curran WJ, Furuse K, Fournel P, Belderbos J, Clamon G, Ulutin HC, Paulus R, Yamanaka T, Bozonnat MC, Uitterhoeve A, Wang X, Stewart L, Arriagada R, Burdett S, Pignon JP (2010) Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer. J Clin Oncol 28(13):2181–2190. https://doi.org/10.1200/JCO.2009.26.2543

Article  PubMed  Google Scholar 

Cerfolio RJ, Ojha B, Bryant AS, Raghuveer V, Mountz JM, Bartolucci AA (2004) The accuracy of integrated PET-CT compared with dedicated PET alone for the staging of patients with nonsmall cell lung cancer. Ann Thorac Surg 78(3):1017–1023. https://doi.org/10.1016/j.athoracsur.2004.02.067

Article  PubMed  Google Scholar 

Flentje M, Huber RM, Engel-Riedel W, Andreas S, Kollmeier J, Staar S, Dickgreber N, Vaissiere N, De Almeida C, Edlich B, Fietkau R (2016) GILT–a randomised phase III study of oral vinorelbine and cisplatin with concomitant radiotherapy followed by either consolidation therapy with oral vinorelbine and cisplatin or best supportive care alone in stage III non-small cell lung cancer. Strahlenther Onkol 192(4):216–222. https://doi.org/10.1007/s00066-016-0941-8

Article  PubMed  Google Scholar 

Florsch B, Taugner J, Kasmann L, Kenndoff S, Guggenberger J, Tufman A, Reinmuth N, Duell T, Belka C, Eze C, Manapov F (2023) Treatment patterns and prognosis of patients with inoperable stage III NSCLC after completion of concurrent chemoradiotherapy +/- immune checkpoint inhibition: a decade-long single-center historical analysis. J Cancer Res Clin Oncol 149(7):3267–3276. https://doi.org/10.1007/s00432-022-04174-z

Article  PubMed  Google Scholar 

Friedes C, Iocolano M, Lee SH, Li B, Duan L, Levin WP, Cengel KA, Sun LL, Aggarwal C, Marmarelis ME, Doucette A, Cohen RB, Xiao Y, Langer CJ, Bradley J, Feigenberg SJ, Yegya-Raman N (2024) Patterns of failure, low-volume relapse, and subsequent ablative management in locally advanced non-small cell lung cancer treated with definitive chemoradiation and consolidation immune checkpoint inhibitors. Int J Radiat Oncol Biol Phys. https://doi.org/10.1016/j.ijrobp.2023.10.005

Article  PubMed  Google Scholar 

Garg S, Gielda BT, Kiel K, Turian JV, Fidler MJ, Batus M, Bonomi P, Sher DJ (2014) Patterns of locoregional failure in stage III non-small cell lung cancer treated with definitive chemoradiation therapy. Pract Radiat Oncol. https://doi.org/10.1016/j.prro.2013.12.002

Article  PubMed  Google Scholar 

Hofstetter K, Taugner J, Kasmann L, Mansoorian S, Florsch B, Eze C, Tufman A, Reinmuth N, Duell T, Belka C, Manapov F (2024) First-site-metastasis pattern in patients with inoperable stage III NSCLC treated with concurrent chemoradiotherapy with or without immune check-point inhibition: a retrospective analysis. Strahlenther Onkol. https://doi.org/10.1007/s00066-023-02175-6

Article  PubMed  Google Scholar 

Kakiuchi Y, Saruwatari K, Murotani K, Tokito T, Iriki T, Iwakawa J, Sakata Y, Shingu N, Saeki S, Inaba M, Takaki A, Misono S, Suetsugu T, Azuma K, Mizuno K, Sakagami T (2024) Real-world efficacy and safety of durvalumab administration following chemoradiotherapy in elderly patients with unresectable locally advanced nonsmall cell lung cancer: a multicenter retrospective Study. Clin Lung Cancer. https://doi.org/10.1016/j.cllc.2024.07.001

Article  PubMed  Google Scholar 

Katagiri Y, Jingu K, Yamamoto T, Matsushita H, Umezawa R, Ishikawa Y, Takahashi N, Takeda K, Tasaka S, Kadoya N (2021) Differences in patterns of recurrence of squamous cell carcinoma and adenocarcinoma after radiotherapy for stage III non-small cell lung cancer. Jpn J Radiol. https://doi.org/10.1007/s11604-021-01091-y

Article  PubMed  Google Scholar 

Kita N, Tomita N, Takaoka T, Sudo S, Tsuzuki Y, Okazaki D, Niwa M, Torii A, Takano S, Niimi A, Hiwatashi A (2023) Comparison of recurrence patterns between adenocarcinoma and squamous cell carcinoma after stereotactic body radiotherapy for early-stage lung cancer. Cancers (Basel). https://doi.org/10.3390/cancers15030887

Article  PubMed  Google Scholar 

Lardinois D, Weder W, Hany TF, Kamel EM, Korom S, Seifert B, von Schulthess GK, Steinert HC (2003) Staging of non-small-cell lung cancer with integrated positron-emission tomography and computed tomography. N Engl J Med 348(25):2500–2507. https://doi.org/10.1056/NEJMoa022136

Article  PubMed  Google Scholar 

Lu S, Kato T, Dong X, Ahn MJ, Quang LV, Soparattanapaisarn N, Inoue T, Wang CL, Huang M, Yang JC, Cobo M, Ozguroglu M, Casarini I, Khiem DV, Sriuranpong V, Cronemberger E, Takahashi T, Runglodvatana Y, Chen M, Investigators LT (2024) Osimertinib after Chemoradiotherapy in Stage III EGFR-Mutated NSCLC. N Engl J Med. https://doi.org/10.1056/NEJMoa2402614

Article  PubMed  PubMed Central  Google Scholar 

Nakamura M, Kageyama SI, Niho S, Okumura M, Hojo H, Motegi A, Nakamura N, Zenda S, Yoh K, Goto K, Akimoto T (2019) Impact of EGFR mutation and ALK translocation on recurrence pattern after definitive chemoradiotherapy for inoperable stage III non-squamous non-small-cell lung cancer. Clin Lung Cancer. https://doi.org/10.1016/j.cllc.2019.02.021

Article  PubMed  Google Scholar 

Nestle U, De Ruysscher D, Ricardi U, Geets X, Belderbos J, Pottgen C, Dziadiuszko R, Peeters S, Lievens Y, Hurkmans C, Slotman B, Ramella S, Faivre-Finn C, McDonald F, Manapov F, Putora PM, LePechoux C, Van Houtte P (2018) ESTRO ACROP guidelines for target volume definition in the treatment of locally advanced non-small cell lung cancer. Radiother Oncol 127(1):1–5. https://doi.org/10.1016/j.radonc.2018.02.023

Article  PubMed  Google Scholar 

Noriko K, Yukinori M, Takashi S, Masakazu O, Takamasa M, Norio A, Kota F, Setsuko O, Kiyoshi N, Takahiro K, Tomoko A, Takashi S, Shuji O, Tomohiro K, Masaru N, Satsuki F, Yusuke I, Hiroaki O, Toyohiro H, Takashi M, Kyoto R (2023) Oncology Study Group (KROSG), Recurrence patterns and progression-free survival after chemoradiotherapy with or without consolidation durvalumab for stage III non-small cell lung cancer, J Radiation Res 64(1):142–153 https://doi.org/10.1093/jrr/rrac057

Nygard L, Vogelius IR, Fischer BM, Kjaer A, Langer SW, Aznar MC, Persson GF, Bentzen SM (2018) A competing risk model of first failure site after definitive chemoradiation therapy for locally advanced non-small cell lung cancer. J Thorac Oncol 13(4):559–567. https://doi.org/10.1016/j.jtho.2017.12.011

Article  PubMed  Google Scholar 

O’Rourke N, Roque IFM, Farre Bernado N, Macbeth F (2010) Concurrent chemoradiotherapy in non-small cell lung cancer. Cochrane Database Syst Rev. https://doi.org/10.1002/14651858.CD002140.pub3

Article  PubMed  Google Scholar 

Rutkowski J, Saad ED, Burzykowski T, Buyse M, Jassem J (2019) Chronological trends in progression-free, overall, and post-progression survival in first-line therapy for advanced NSCLC. J Thorac Oncol. https://doi.org/10.1016/j.jtho.2019.05.030

Article  PubMed  Google Scholar 

Sause WT, Scott C, Taylor S, Johnson D, Livingston R, Komaki R, Emami B, Curran WJ, Byhardt RW, Turrisi AT et al (1995) Radiation Therapy Oncology Group (RTOG) 88-08 and Eastern Cooperative Oncology Group (ECOG) 4588: preliminary results of a phase III trial in regionally advanced, unresectable non-small-cell lung cancer. J Natl Cancer Inst. https://doi.org/10.1093/jnci/87.3.198

Article  PubMed  Google Scholar 

Schneider BJ, Ismaila N, Aerts J, Chiles C, Daly ME, Detterbeck FC, Hearn JWD, Katz SI, Leighl NB, Levy B, Meyers B, Murgu S, Nekhlyudov L, Santos ES, Singh N, Tashbar J, Yankelevitz D, Altorki N (2020) Lung cancer surveillance after definitive curative-intent therapy: ASCO guideline. J Clin Oncol. https://doi.org/10.1200/JCO.19.02748

Article  PubMed  Google Scholar 

Taugner J, Kasmann L, Eze C, Dantes M, Roengvoraphoj O, Gennen K, Karin M, Petruknov O, Tufman A, Belka C, Manapov F (2019) Survival score to characterize prognosis in inoperable stage III NSCLC after chemoradiotherapy. Transl Lung Cancer Res. https://doi.org/10.21037/tlcr.2019.09.19

Article  PubMed  PubMed Central  Google Scholar 

Taugner J, Eze C, Kasmann L, Roengvoraphoj O, Gennen K, Karin M, Petrukhnov O, Tufman A, Belka C, Manapov F (2020) Pattern-of-failure and salvage treatment analysis after chemoradiotherapy for inoperable stage III non-small cell lung cancer. Radiat Oncol. https://doi.org/10.1186/s13014-020-01590-8

Article  PubMed  PubMed Central  Google Scholar 

Taugner J, Kasmann L, Eze C, Ruhle A, Tufman A, Reinmuth N, Duell T, Belka C, Manapov F (2021) Real-world prospective analysis of treatment patterns in durvalumab maintenance after chemoradiotherapy in unresectable, locally advanced NSCLC patients. Invest New Drugs. https://doi.org/10.1007/s10637-021-01091-9

Article  PubMed  PubMed Central  Google Scholar 

Unterrainer M, Taugner J, Kasmann L, Tufman A, Reinmuth N, Li M, Mittlmeier LM, Bartenstein P, Kunz WG, Ricke J, Belka C, Eze C, Manapov F (2022) Differential role of residual metabolic tumor volume in inoperable stage III NSCLC after chemoradiotherapy +/- immune checkpoint inhibition. Eur J Nucl Med Mol Imaging. https://doi.org/10.1007/s00259-021-05584-w

Article  PubMed  PubMed Central